Bioxcel Therapeutics Inc (BTAI) Stock Price, Quote & News

Company Profile

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 475 238 6837

Website: www.bioxceltherapeutics.com

Address:

555 Long Wharf Drive, 12th Floor, New Haven, United States

BigDicBandit Feb. 23 at 9:23 PM

$BTAI can’t believe we broke out the 50’s

0 · Reply

WenABVEAudit Feb. 23 at 6:52 PM

$BTAI these dumbasses are probably just sitting on their hands until eoy approval or not

1 · Reply

Ernesto62 Feb. 23 at 4:46 PM

$BTAI since 3 yrs ceo talks about it

1 · Reply

0utsider Feb. 23 at 1:52 PM

$BTAI maybe not today, not tomorrow but one day…

0 · Reply

BayAreaBiotech Feb. 22 at 5:02 AM

$BTAI a partnership is more critical now than ever. It would provide not only much-needed capital but also external validation and meaningful commercial leverage. A strategic partner could materially improve execution probability, particularly for the TRANQUILITY program targeting agitation in Alzheimer’s dementia. Otsuka Pharmaceutical would be a highly credible partner of choice. There may already be partnership interest contingent on FDA progress for the at-home sNDA. Any discussions could re-emerge upon sNDA acceptance, but a definitive deal is more likely following regulatory approval.

1 · Reply

BayAreaBiotech Feb. 22 at 4:57 AM

$BTAI Approval is never guaranteed, but based on the data it appears very likely. My confidence remains high given the strength of the science and the clear patient need. From here, the key driver isn’t approval itself, but how restrictive the final label will be. The at-home program met its primary endpoint, with exploratory work further validating efficacy using a modified assessment tailored for the home setting.

0 · Reply

DunnoT Feb. 21 at 11:58 AM

Nice potential short term long opportunity for $NCI based on 4 similar events: [Ticker; End date] $KAVL 2022-02-15 $DFLI 2025-10-03 $LIXT 2025-07-03 $BTAI 2025-08-12 1) Expect a drop (-30 - 40%) 2) Re-test previous high (+50 - 70%) https://www.tradingview.com/chart/NCI/hxiiP7Jo-Similar-events-for-NCI/

0 · Reply

fibonacci1170 Feb. 21 at 6:41 AM

$BTAI VNDA's pill has gotten FDA approval for schiz and bipolar (the label doesn't mention at-home or at-clinic, so I guess it is approved in all settings). I imagine a pill is easier to administer to a schiz/bipolar person than sublingual igalmi? Where does this leave BTAI?

2 · Reply

BayAreaBiotech Feb. 21 at 1:34 AM

$BTAI I am glad that I heavily invested in two buyouts (PRVB and RAPT) in the last three years. Hopefully BTAI is the 3rd buyout by 2027. Will accumulate shares at this price. The financial risk is high but the science is strong and patients unmet needs can be addressed by igalmi in the home setting. If the company can survive this year and get sNDA approval, this could be another multi bagger. If Tranquility is successful then it’s a completely different ball game. Bad management but good drug and high patient need. It’s high risk high reward investment but I am a big believer in the science and patient need, therefore, heavily invested in BTAI. I had to live through the pain of seeing the PRVB and RAPT stocks losing so much value and at times doubted the investment but I still patiently waited. Patience paid off and it may be the case here.

1 · Reply

AllAboutTheBread Feb. 21 at 1:20 AM

$BTAI sorry boys i was wrong this week. always next week.

0 · Reply

BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer's Dementia

Jan 20, 2026, 7:00 AM EST - 4 weeks ago

BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting

Jan 15, 2026, 12:44 PM EST - 5 weeks ago

Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Jan 12, 2026, 7:00 AM EST - 6 weeks ago

BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting

Jan 7, 2026, 7:00 AM EST - 6 weeks ago

BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®

Dec 11, 2025, 6:42 AM EST - 2 months ago

BioXcel Therapeutics, Inc. (BTAI) Discussion of Managing Acute Agitation in Schizophrenia and Bipolar Disorders at Home Transcript

Dec 3, 2025, 7:00 AM EST - 2 months ago

Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions

Nov 12, 2025, 7:00 AM EST - 3 months ago

BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer's Disease

Oct 14, 2025, 7:00 AM EDT - 4 months ago

BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes

Oct 13, 2025, 7:00 AM EDT - 4 months ago

BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation

Sep 18, 2025, 7:00 AM EDT - 5 months ago

BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements

Sep 10, 2025, 6:41 PM EDT - 5 months ago

BioXcel Therapeutics, Inc. (BTAI) Discuses On SERENITY At-Home Pivotal Phase 3 Safety Trial Results Call (Transcript)

Sep 10, 2025, 3:08 PM EDT - 5 months ago

BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar Patients

Sep 10, 2025, 6:30 AM EDT - 5 months ago

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia

Sep 4, 2025, 7:00 AM EDT - 6 months ago

BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 12:01 PM EDT - 6 months ago

BioXcel Seeks FDA Label Expansion For Schizophrenia Treatment

Aug 27, 2025, 8:00 AM EDT - 6 months ago

UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

Aug 27, 2025, 7:29 AM EDT - 6 months ago

BioXcel's agitation drug meets main goal in at-home study

Aug 27, 2025, 7:00 AM EDT - 6 months ago

BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

Aug 26, 2025, 4:00 PM EDT - 6 months ago

BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025

Aug 19, 2025, 7:00 AM EDT - 6 months ago

BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Aug 18, 2025, 7:00 AM EDT - 6 months ago

BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia

Aug 13, 2025, 7:00 AM EDT - 6 months ago

BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series

Aug 12, 2025, 7:55 AM EDT - 6 months ago

BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates

Aug 11, 2025, 7:00 AM EDT - 7 months ago

BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference

Aug 6, 2025, 7:00 AM EDT - 7 months ago

BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies

Aug 1, 2025, 7:00 AM EDT - 7 months ago

BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Jul 21, 2025, 7:00 AM EDT - 7 months ago

BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI®

Jul 1, 2025, 7:00 AM EDT - 8 months ago

BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

May 27, 2025, 8:01 AM EDT - 9 months ago

BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

May 27, 2025, 7:00 AM EDT - 9 months ago

BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement

May 12, 2025, 7:00 AM EDT - 10 months ago

BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Mar 27, 2025, 7:00 AM EDT - 11 months ago

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

Mar 11, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Mar 7, 2025, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Mar 4, 2025, 4:15 PM EST - 1 year ago

BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering

Mar 3, 2025, 3:33 PM EST - 1 year ago

BioXcel Therapeutics Announces $14 Million Registered Direct Offering

Mar 3, 2025, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer's Dementia

Feb 28, 2025, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 6, 2025, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Announces Reverse Stock Split

Nov 22, 2024, 8:16 AM EST - 1 year ago

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

Nov 21, 2024, 4:47 PM EST - 1 year ago

BioXcel Therapeutics Announces Proposed Public Offering

Nov 14, 2024, 9:07 AM EST - 1 year ago

BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 7:00 AM EST - 1 year ago

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

Oct 29, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics to Present at ThinkEquity Conference

Oct 15, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

Sep 19, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation

Sep 5, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Aug 9, 2024, 9:48 PM EDT - 1 year ago

BioXcel Therapeutics, Inc. (BTAI) Q2 2024 Earnings Call Transcript

Jul 16, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film

BigDicBandit Feb. 23 at 9:23 PM

$BTAI can’t believe we broke out the 50’s

0 · Reply

WenABVEAudit Feb. 23 at 6:52 PM

$BTAI these dumbasses are probably just sitting on their hands until eoy approval or not

1 · Reply

Ernesto62 Feb. 23 at 4:46 PM

$BTAI since 3 yrs ceo talks about it

1 · Reply

0utsider Feb. 23 at 1:52 PM

$BTAI maybe not today, not tomorrow but one day…

0 · Reply

BayAreaBiotech Feb. 22 at 5:02 AM

1 · Reply

BayAreaBiotech Feb. 22 at 4:57 AM

0 · Reply

DunnoT Feb. 21 at 11:58 AM

0 · Reply

fibonacci1170 Feb. 21 at 6:41 AM

2 · Reply

BayAreaBiotech Feb. 21 at 1:34 AM

1 · Reply

AllAboutTheBread Feb. 21 at 1:20 AM

$BTAI sorry boys i was wrong this week. always next week.

0 · Reply

Thekiss320 Feb. 20 at 10:36 AM

$BTAI

0 · Reply

SrTxan Feb. 19 at 3:24 PM

$BTAI New positions this quarter

2 · Reply

SrTxan Feb. 19 at 2:41 PM

$BTAI Two Sigma Securities, Llc ownership in BTAI / BioXcel Therapeutics, Inc. On February 17, 2026 - Two Sigma Securities, Llc filed a 13F-HR form disclosing ownership of 17,068 shares of BioXcel Therapeutics, Inc. (US:BTAI) valued at $27,309 USD as of December 31, 2025. The entity filed a previous 13F-HR on May 15, 2025 disclosing 0 shares of BioXcel Therapeutics, Inc.. The current value of the position is $26,967 USD.

0 · Reply

SrTxan Feb. 19 at 12:59 PM

$BTAI While the forum screams disaster, the filings say something else Millennium +78% now at 8.4% of the float Vanguard +52% Geode +64% GSA entered Man Group long Engineers Gate entered Who exited? XTX, a quantitative market maker that constantly rotates positions and may trade short On February 17, 2026 - XTX Topco Ltd filed a 13F-HR form disclosing ownership of 0 shares of BioXcel Therapeutics, Inc. (US:BTAI) valued at $0 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 14, 2025 disclosing 113,364 shares of BioXcel Therapeutics, Inc.. This represents a change in shares of -100.00% during the quarter. The current value of the position is $0 USD. Less drama, more SEC.

0 · Reply

SrTxan Feb. 19 at 12:43 PM

$BTAI Man Group plc ownership in BTAI / BioXcel Therapeutics, Inc. On February 17, 2026 - Man Group plc filed a 13F-HR form disclosing ownership of 56,825 shares of BioXcel Therapeutics, Inc. (US:BTAI) valued at $90,920 USD as of December 31, 2025. The current value of the position is $89,784 USD.

0 · Reply

SrTxan Feb. 19 at 12:42 PM

$BTAI Engineers Gate Manager LP ownership in BTAI / BioXcel Therapeutics, Inc. On February 17, 2026 - Engineers Gate Manager LP filed a 13F-HR form disclosing ownership of 12,303 shares of BioXcel Therapeutics, Inc. (US:BTAI) valued at $19,685 USD as of December 31, 2025. The entity filed a previous 13F-HR on May 15, 2025 disclosing 0 shares of BioXcel Therapeutics, Inc.. The current value of the position is $19,439 USD.

0 · Reply

SrTxan Feb. 19 at 12:41 PM

$BTAI Jones Financial Companies Lllp reports 282.47% increase in ownership of BTAI / BioXcel Therapeutics, Inc. On February 17, 2026 - Jones Financial Companies Lllp filed a 13F-HR form disclosing ownership of 137,690 shares of BioXcel Therapeutics, Inc. (US:BTAI) valued at $220,304 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 4, 2025 disclosing 36,000 shares of BioXcel Therapeutics, Inc.. This represents a change in shares of 282.47% during the quarter. The current value of the position is $217,550 USD.

0 · Reply

DARKP00L Feb. 19 at 12:20 PM

$BTAI 07:08 on Feb. 19 2026 BioXcel Therapeutics To Hold Virtual KOL Roundtable On February 27 Highlighting ~100M Annual Alzheimer's Agitation Episodes And Lack Of FDA-Approved Treatments #tradeideas

0 · Reply

TheTradeXchange Feb. 19 at 12:01 PM

$BTAI - BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer’s Dementia

0 · Reply

TheDude2778 Feb. 19 at 12:03 AM

$BTAI —- Remember last year we priced at $60/share, and then a later revision came in around so,ethereal at $10? Management has fubar’d any real movement to gain attraction w bigger pharma’s (as in a buyout) to accommodate an infrastructure to keep up w future demand for Iglami

1 · Reply

wndyctyboy1975 Feb. 18 at 11:44 PM

$BTAI us trying to gwt this to move

0 · Reply

Dan1019 Feb. 18 at 9:56 PM

$BTAI this, is going to be a long wait! They submitted for FDA approval in January 14, 2026. So, that has only been one month since. June or October is my guess before we hear anything.

1 · Reply

Market Cap	34.33M
Revenue (ttm)	2.27M
Net Income (ttm)	-59.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,625.55%
Debt to Equity Ratio	-1.23

Volume	325,156
Avg Vol	496,036
Day's Range	N/A - N/A
Shares Out	21.87M
Stochastic %K	40%
Beta	0.22
Analysts	Sell
Price Target	$15.25